Plasma pTau181 and pTau217 predict asymptomatic amyloid accumulation equally well as amyloid PET
Brain Communications · 02.07.2024 · 6 (4)
DOI: 10.1093/braincomms/fcae162 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain Communications, online erschienen am 23.05.2024. Verfasst von Steffi De Meyer und 16 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Cognitive Neurology, Department of Neurosciences, Leuven Brain Institute (LBI), KU Leuven, 3000 Leuven, Belgium. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vlaamse Impulsfinanciering voor Netwerken voor Dementie-onderzoek, Stichting Alzheimer Onderzoek, Vlaams Agentschap van Innoveren en Ondernemen—Interdisciplinair Coöperatief Onderzoek.
Abstract (Originalsprache)
The dynamic phase of preclinical Alzheimer’s disease, as characterized by accumulating cortical amyloid-β, is a window of opportunity for amyloid-β–lowering therapies to have greater efficacy. Biomarkers that accurately predict amyloid-β accumulation may be of critical importance for participant inclusion in secondary prevention trials and thus enhance development of early Alzheimer’s disease therapies. We compared the abilities of baseline plasma pTau181, pTau217 and amyloid-β PET load to predict future amyloid-β accumulation in asymptomatic elderly. In this longitudinal cohort study, baseline plasma pTau181 and pTau217 were quantified using single molecule array assays in cognitively unimpaired elderly selected from the community-recruited F-PACK cohort based on the availability of baseline plasma samples and longitudinal amyloid-β PET data (median time interval = 5 years, range 2–10 years). The predictive abilities of pTau181, pTau217 and PET-based amyloid-β measures for PET-based amyloid-β accumulation were investigated using receiver operating characteristic analyses, correlations and stepwise regression analyses. We included 75 F-PACK subjects (mean age = 70 years, 48% female), of which 16 were classified as amyloid-β accumulators [median (interquartile range) Centiloid rate of change = 3.42 (1.60) Centiloids/year). Plasma pTau181 [area under the curve (95% confidence interval) = 0.72 (0.59–0.86)] distinguished amyloid-β accumulators from non-accumulators with similar accuracy as pTau217 [area under the curve (95% confidence interval) = 0.75 (0.62–0.88) and amyloid-β PET [area under the curve (95% confidence interval) = 0.72 (0.56–0.87)]. Plasma pTau181 and pTau217 strongly correlated with each other (r = 0.93, Pfalse discovery rate < 0.001) and, together with amyloid-β PET, similarly correlated with amyloid-β rate of change (rpTau181 = 0.33, rpTau217 = 0.36, ramyloid-β PET = 0.35, all Pfalse discovery rate ≤ 0.01). Addition of plasma pTau181, plasma pTau217 or amyloid-β PET to a linear demographic model including age, sex and APOE-ε4 carriership similarly improved the prediction of amyloid-β accumulation (ΔAkaike information criterion ≤ 4.1). In a multimodal biomarker model including all three biomarkers, each biomarker lost their individual predictive ability. These findings indicate that plasma pTau181, plasma pTau217 and amyloid-β PET convey overlapping information and therefore predict the dynamic phase of asymptomatic amyloid-β accumulation with comparable performances. In clinical trial recruitment, confirmatory PET scans following blood-based prescreening might thus not provide additional value for detecting participants in these early disease stages who are destined to accumulate cortical amyloid-β. Given the moderate performances, future studies should investigate whether integrating plasma pTau species with other factors can improve performance and thus enhance clinical and research utility.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory for Cognitive Neurology, Department of Neurosciences, Leuven Brain Institute (LBI), KU Leuven, 3000 Leuven, Belgium.
- Laboratory for Molecular Neurobiomarker Research, Department of Neurosciences, Leuven Brain Institute (LBI), KU Leuven, 3000 Leuven, Belgium.
- Laboratory for Complex Genetics, Department of Human Genetics, KU Leuven, 3000 Leuven, Belgium.
- Neurochemistry Laboratory, Department of Clinical Chemistry, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, 1081 HV Amsterdam, The Netherlands.
- Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, 3000 Leuven, Belgium.
- Division of Nuclear Medicine, UZ Leuven, 3000 Leuven, Belgium.
ORCID-Profile: Steffi De Meyer, Emma S Luckett, Mariska Reinartz, Isabelle Cleynen, Henrik Zetterberg, Charlotte E Teunissen, Koen Poesen, Rik Vandenberghe
Förderung
- Vlaamse Impulsfinanciering voor Netwerken voor Dementie-onderzoek
- Stichting Alzheimer Onderzoek
- Vlaams Agentschap van Innoveren en Ondernemen—Interdisciplinair Coöperatief Onderzoek
- Katholieke Universiteit Leuven Bijzonder Onderzoeksfonds
- Fonds Wetenschappelijk Onderzoek Vlaanderen
- Swedish Research Council
- European Union’s Horizon Europe
- Swedish State Support for Clinical Research
Zitieren
APA
De Meyer, S., Schaeverbeke, J. M., Luckett, E. S., Reinartz, M., Blujdea, E. R., Cleynen, I., Dupont, P., Van Laere, K., Vanbrabant, J., Stoops, E., Vanmechelen, E., di Molfetta, G., Zetterberg, H., Ashton, N. J., Teunissen, C. E., Poesen, K., & Vandenberghe, R. (2024). Plasma pTau181 and pTau217 predict asymptomatic amyloid accumulation equally well as amyloid PET. Brain Communications, 6(4). https://doi.org/10.1093/braincomms/fcae162
Vancouver
De Meyer S, Schaeverbeke JM, Luckett ES, Reinartz M, Blujdea ER, Cleynen I, et al. Plasma pTau181 and pTau217 predict asymptomatic amyloid accumulation equally well as amyloid PET. Brain Communications. 2024;6(4). doi:10.1093/braincomms/fcae162
BibTeX
@article{DeMeyer2024,
author = {De Meyer, Steffi and Schaeverbeke, Jolien M and Luckett, Emma S and Reinartz, Mariska and Blujdea, Elena R and Cleynen, Isabelle and Dupont, Patrick and Van Laere, Koen and Vanbrabant, Jeroen and Stoops, Erik and Vanmechelen, Eugeen and di Molfetta, Guglielmo and Zetterberg, Henrik and Ashton, Nicholas J and Teunissen, Charlotte E and Poesen, Koen and Vandenberghe, Rik},
title = {Plasma pTau181 and pTau217 predict asymptomatic amyloid accumulation equally well as amyloid PET},
journal = {Brain Communications},
year = {2024},
volume = {6},
number = {4},
doi = {10.1093/braincomms/fcae162}
}
EUVIMED